149 results about "Immunity active" patented technology

The invention discloses application of a broad-spectrum influenza virus polypeptide vaccine in preparation of a medicine for preventing influenza virus infection and controlling influenza virus reinfection, and belongs to the technical field of biological medicine. The vaccine is designed on the basis of artificially synthesized polypeptide, a polypeptide sequence which is highly conservative and has immunocompetence is screened and optimized aiming at various subtype influenza virus proteins, a broad-spectrum polypeptide vaccine P125-H is constructed, and an Ii-Key technology and an MF59 adjuvant are applied to enhance immune response. The vaccine can effectively induce immune protection against H1N1 and H7N9 influenza A viruses, significantly reduce the virus load, reduce pathological injury to the lung and improve the survival rate. The P125-H vaccine is composed of three optimized polypeptides, has a cross protection effect on various influenza virus subtypes, has the potential of being developed into a broad-spectrum influenza vaccine, and provides a new technical scheme for coping with influenza virus variation and improving vaccine efficacy.

The invention discloses an enzymolysis preparation method of high-immunocompetence bovine coloctrum peptide, active peptide and application thereof, and belongs to the field of biotechnology and functional foods.The enzymolysis preparation method is characterized by comprising the steps that bovine coloctrum is degreased, trehalose is added into obtained supernate, first stirring is conducted, and first mixed liquid is obtained; wherein the supernate comprises whey protein and Ig; adding medium protease into the first mixed solution for hydrolysis to obtain enzymatic hydrolysate; wherein the enzymatic hydrolysate comprises a mixture of bovine colostrum hydrolyzed peptides, the Ig activity retention rate is larger than or equal to 90% through the targeted protection and directional enzymolysis technology, the beta-lactoglobulin peptide with the synergistic immune enhancement effect is obtained, the Ig and small molecule peptides in the product have the synergistic effect, the body immune regulation capacity and the intestinal immune function are remarkably improved, the immunity of the human body is improved, and the immunity of the human body is improved. The method can be widely applied to the fields of infant formulas, postoperative nutrition, functional drinks and the like.

The invention provides a tuberculosis mRNA vaccine as well as a preparation method and application thereof. The invention firstly provides an antigen, which comprises the following antigen components: at least one fusion protein or chimeric protein formed by mycobacterium tuberculosis early secretion antigens Ag85A and Ag85B and / or immunocompetence fragments thereof, at least one mycobacterium tuberculosis PE / PPE family antigen Rv1759c (PE-PGRS family protein WAG22) or immunocompetence fragments thereof, and at least one immunocompetence fragment thereof, and at least one mycobacterium tuberculosis latent associated antigen Rv1813c or an immunocompetence fragment thereof; selectively, two or more of these antigens or immunocompetent fragments thereof may form a fusion protein and / or chimeric protein as an antigen component. The mRNA vaccine with multiple antigen components has a more effective effect on prevention of tuberculosis.

The application discloses a method for preparing cell-derived exosomes and products and applications thereof, and the method comprises the following steps: co-culturing immune-activated programmable cells with a stimulating agent with immune-activation effect, and collecting the cell-derived exosomes with immune activity by a natural secretion collection method or an artificial extrusion collection method. The application has safe and controllable local immune activation, and the immune activation strategy based on the exosomes fully overcomes the safety bottleneck of traditional live bacterial preparations in tumor treatment. By replacing live bacteria with engineered exosomes, not only potential risks such as systemic inflammatory response and infection are effectively avoided, but also the local controllability of immune stimulation signals is ensured, the precise activation and directional regulation of tumor region immune cells are realized, the tumor microenvironment is reshaped, the anti-tumor effect is strengthened, and the broad-spectrum cross-tumor potential is verified across models.

Disclosed are an mRNA pharmaceutical composition for preventing and treating tuberculosis and use thereof. The mRNA pharmaceutical composition comprises: an mRNA molecule encoding a Mycobacterium tuberculosis antigen, and a pharmaceutically acceptable excipient. The Mycobacterium tuberculosis antigen comprises the following antigen components: at least one early-secreted antigen of Mycobacterium tuberculosis or an immunologically active fragment thereof; PE / PPE family antigen WAG22 of Mycobacterium tuberculosis or an immunologically active fragment thereof; and at least one latent-related antigen of Mycobacterium tuberculosis or an immunologically active fragment thereof. The mRNA pharmaceutical composition does not comprise or further comprises an mRNA molecule encoding a cytokine. The pharmaceutical composition is used for preparing a tuberculosis vaccine, which may serve as a prophylactic vaccine for preventing latent activation or as a therapeutic drug for treating active tuberculosis, exhibiting a significant inhibitory effect on Mycobacterium tuberculosis.

The present application relates to the technical field of molecular biology, and particularly relates to a human parainfluenza virus type I HN recombinant antigen and application thereof. The amino acid sequence of the human parainfluenza virus type I recombinant HN recombinant antigen provided by the present application is shown as SEQ ID NO:1. The amino acid sequence provided by the present application can be efficiently expressed in insect cells, and a stable antigen can be obtained after purification and preparation of the expression product, and the antigen has high immunological activity and can be used for serum specific antibody detection or parainfluenza virus infection diagnosis.

The invention provides an mRNA (messenger ribonucleic acid) pharmaceutical composition for preventing and treating tuberculosis and application of the mRNA pharmaceutical composition. The mRNA pharmaceutical composition for preventing and treating tuberculosis comprises mRNA molecules for coding mycobacterium tuberculosis antigens and pharmaceutically acceptable auxiliary materials, the mycobacterium tuberculosis antigen comprises the following antigen components: at least one mycobacterium tuberculosis early secretion antigen or an immunocompetence fragment thereof; a mycobacterium tuberculosis PE / PPE family antigen Rv3872 or an immunocompetence fragment thereof; and at least one mycobacterium tuberculosis latent associated antigen or an immunocompetent fragment thereof; the mRNA pharmaceutical composition does not include or further includes an mRNA molecule encoding a cytokine. The pharmaceutical composition provided by the invention is used for preparing tuberculosis vaccines, can be used as a prophylactic vaccine for preventing latent activation, can also be used as a therapeutic drug for treating active tuberculosis, and has a remarkable inhibition effect on mycobacterium tuberculosis.

Described herein are compositions and methods for treating or preventing skin or ocular surface disorders, such as those associated with bacterial and / or parasitic infections. Bacterial and / or parasitic infections include mites (e.g., Demodex), helminths, protozoa (e.g., amebas (e.g., Acanthamoeba or Cryptosporidiosis)), onchocerciasis, lice, scabies, nematodes, or chlamydia. The compositions and methods include compounds that exhibit immunological activity, keratolytic activity, antihistamine activity, anti-inflammatory activity, and / or other desirable activities. Topical administration of the compositions to the eyelid margin or surrounding area provides therapeutic benefit to patients with ocular surface disorders.

The invention discloses a double-target chimeric antigen receptor capable of simultaneously targeting TLL1 and B7H3, a CAR-T cell and application of the double-target chimeric antigen receptor. The chimeric antigen receptor is a fusion protein which is sequentially composed of Omburt-scFv (SEQ ID NO: 1) targeting B7H3, a CD8 alpha hinge region and transmembrane region, a 4-1BB costimulatory domain, a CD3 zeta signal domain and TLL1-scFv (SEQ ID NO: 6) targeting TLL1 from an N terminal to a C terminal. The TLL1-scFv can be efficiently combined with TLL1 protein, can inhibit a TGF-beta signal channel and block prostate cancer cell migration, and is integrated into CAR of targeted B7H3, so that the double-target CAR-T cell with direct killing and immune microenvironment regulation functions is successfully constructed. The CAR-T cell has a remarkable killing effect on a prostate cancer cell line DU145, can be strongly activated after being co-cultured with a target cell and secretes a large amount of IFN-gamma and TNF-alpha, and shows high immunocompetence. The invention provides a new synergistic immunotherapy strategy for the B7H3-positive prostate cancer with the TGF-beta signal channel activated.

An antibody or antibody derivative having a higher immune checkpoint inhibitory effect. The antibody or antibody derivative is capable of enhancing immune activity against cancer cells, and can be used to treat cancer. The antibody is a heterodimeric antibody or antibody derivative capable of binding to both the TIM-3 and CD39 antigens. The heterodimeric antibody or antibody derivative is capable of enhancing immune activity against cancer cells.

The invention relates to the technical field of biomedicine, in particular to an immunoregulation chiral material as well as a preparation method and application thereof, and the immunoregulation chiral material is formed by self-assembly of an immune active component and a delivery carrier. The immunocompetence component is selected from chiral peptide modified distearoyl phosphatidyl ethanolamine-polyethylene glycol, and the chiral peptide is formed by connecting 6-10 D-alanine monomers through amido bonds. The material can realize accurate targeting on target cells by virtue of specific three-dimensional recognition of chiral peptides and immune cell surface receptors, and reduces non-specific action on normal tissues; a delivery carrier represented by lipid nanoparticles can effectively protect chiral peptides from in-vivo enzymolysis and improve the cycling stability of the chiral peptides, and natural carriers such as exosomes can enhance the biocompatibility and tissue penetrability of the material, so that a new strategy is provided for immunotherapy of diseases such as tumors and the like; the compound is expected to be applied to clinical treatment as a novel immunotherapy drug.

The invention belongs to the technical field of whey protein processing, and particularly relates to a preparation method of a hydrolyzed whey protein digestion product with high immunocompetence and low sensitization. The preparation method comprises the following steps: by taking hydrolyzed whey protein as a raw material, carrying out simulated gastrointestinal digestion treatment under specific conditions to obtain a whey protein digestion product; the product can effectively exert immunoregulation and anti-inflammatory effects, solves the problem of sensitization of a traditional whey protein product, and has a good application prospect.

The application provides a preparation method of high-selenium compound powder for postoperative and radiotherapy rehabilitation immune repair, and belongs to the technical field of functional food or special medical use formula food processing technology.The application realizes sufficient wall breaking by respectively pre-wetting and low-temperature complex enzymolysis of hard plant wall and fungal wall raw materials, and then prevents active loss by using endogenous substances of the raw materials for in-situ anchoring without adding, after drying and crushing, adding postbiotic powder, active peptide, whey protein, yeast beta-glucan, EGCG and other heat-sensitive components into low-temperature sterile dry mixing, while maximizing the release of organic selenium and immune active substances, the heat-sensitive functional components are completely protected from degradation and inactivation, and finally the technical target of sufficient wall breaking, complete activity and stable immune repair effect is achieved.The product prepared by the application can improve the immune organ damage and immune homeostasis imbalance caused by radiotherapy, and is suitable for the immune repair of postoperative and radiotherapy rehabilitation population.

The invention discloses an oyster-derived polypeptide and application thereof, and belongs to the technical field of bioactive peptides. The oyster source polypeptide provided by the invention is selected from at least one of the following polypeptide sequences: PAPLWQMPKFRN, NPVDPAPLWQMPK, PFPL, VPPF, PLNF, APAPAVKYLR, PPMIFKTR, PPMIFKTRIM, AVNMVPFPR, FSLP, PFKP, FPSIVGRPR, VPKPYLNHPL, LPPL, PQDVPPKKPLIMIAAR, VPFVPYLNHPL, FLLK, SPPELPDVM and MPVTDPPLRTF. The invention also discloses a preparation method of the oyster source polypeptide. The invention also discloses application of the oyster-derived polypeptide in preparation of food, health care products or medicines with an immune regulation function. The oyster source peptide product disclosed by the invention has digestion stability and immunocompetence, can keep a basic structure after simulating gastric juice digestion, and can activate the immune function of RAW264.7 cells and improve the expression quantity of cell factors. The method provided by the invention can provide a new direction for high-value utilization of marine resources, and has a good application prospect.

The invention discloses design and synthesis of a hapten of cyromazine, development of a cyromazine artificial antigen and a cyromazine antibody, and application of the cyromazine artificial antigen and the cyromazine antibody in the field of food safety rapid detection. The aminocarboxylic acid modified cyromazine hapten product is prepared through the steps of cyromazine hapten design, connecting arm introduction, synthesis, purification and the like. The cyromazine hapten with the structure is coupled with keyhole limpet hemocyanin to form an artificial immune antigen with immunogenicity, and is coupled with chicken ovalbumin to form an artificial competitive antigen. Tests show that the artificial immune antigen has high immunocompetence and can stimulate an animal immune system to generate an anti-cyromazine antibody, and the titer of an immune Blab / c mouse serum antibody is 16000. The IC50 of an enzyme-linked immunosorbent assay (ELISA) detection method established by the cyromazine artificial competitive antigen and the anti-cyromazine antibody is 5.3 [mu] g / L, and the detection sensitivity of an established gold-labeled immunochromatography detection method reaches 50 [mu] g / L.

To provide a novel Lactobacillus paracasei strain with bone regeneration effects, and pharmaceutical and food compositions containing the same. [Solution] The present invention relates to a novel Lactobacillus paracasei L-30 and its uses, and more particularly to Lactobacillus paracasei L-30 (KCTC16035BP) which has the ability to promote the differentiation or formation of osteoblasts, the ability to suppress the differentiation or formation of osteoclasts, and the ability to promote immune activity, and which can regenerate bone, and to a pharmaceutical composition for the treatment or prevention of bone diseases containing the same.

The invention relates to a system for measuring a level of a subject's immune activity (10), the system comprising: - an exhaled air sensor (20), - a device for measuring exhaled air (30), - computation means (40) suitable for determining data relating to the air exhaled by the subject from the measurements carried out by the device (30), - a memory (60) suitable for storing the measurements performed by the device (30) and / or the data calculated by the means (40), and the subject's personal data, - a computation means (70) suitable for determining a level of the subject's immune activity on the basis of at least one item of exhaled air data, generated in real time by the means (40) and / or stored in the memory (60), - a communication and management interface (80) suitable for presenting said level of the subject's immune activity and / or sub-scores of immunological activity, inflammatory activity, digestive inflammation and / or pulmonary inflammation.

The application belongs to the application field of selenium polysaccharide, and particularly relates to application of the selenium polysaccharide in preparation of an immune active agent, wherein the selenium polysaccharide is obtained by treating Cyclobalanopsis glauca with exogenous selenium, has good immune activity, can better promote proliferation and phagocytosis of RAW264.7 macrophages, and has a significant advantage in improving the release amount of NO, and the results show that the polysaccharide after exogenous selenium strengthening has better immune activity. Exogenous selenium strengthening obviously improves the characteristics of the selenium polysaccharide in Cyclobalanopsis glauca leaves, and has better potential in antioxidation and immune improvement, and provides data support for further research and utilization.

This invention belongs to the field of biomedical technology, specifically disclosing the application of a CTL epitope peptide derived from the neoantigen ESR1 or its encoded nucleic acid in the preparation of a drug for treating tumors. Through analysis of the COSMIC database, epitope prediction, and in vitro and in vivo immunomodulatory activity experiments, this invention identified an HLA-A2-restricted CTL epitope peptide derived from the neoantigen ESR1. This mutant epitope peptide originates from a high-frequency mutation of ESR1 and can effectively stimulate and induce the production of neotope-specific cytotoxic T lymphocytes, specifically distinguishing between wild-type and mutant sequences, and killing tumor cells expressing the mutant epitope, exhibiting good anti-tumor effects. The resulting drug for treating tumors may contain the CTL epitope peptide derived from the neoantigen ESR1 or its encoded nucleic acid, or may contain a T-cell receptor, chimeric antigen receptor, or its encoded nucleic acid that specifically recognizes the mutant epitope peptide, demonstrating good therapeutic potential and clinical application prospects.

The application provides an antigen nanoparticle and a preparation method and vaccine preparation application thereof, and relates to the technical field of biotechnology.The antigen nanoparticle provided by the application comprises an antigen and poly( maleic anhydride-ALT-1-octadecene) grafted with polyethylene glycol, the antigen nanoparticle has good stability and high immunocompetence, and can be used for the preparation of a vaccine.The preparation method of the antigen nanoparticle provided by the application is convenient to operate, parameters are controllable, reproducibility is good, and the reaction is carried out in a water environment, the condition is mild, and the influence on the structure of the antigen is small.The vaccine provided by the application comprises the antigen nanoparticle and an adjuvant, and the inventor has found that the antigen nanoparticle and the adjuvant have a synergistic effect, and the combination of the two can further improve the immunization effect of the vaccine.

The invention discloses a drug-loaded nanoparticle as well as a preparation method and application thereof. The drug-loaded nanoparticles comprise active components and a carrier, wherein the active components comprise a hydrophobic small-molecule inhibitor and PAEMA; the carrier comprises an amphiphilic polymer bonded with a photosensitizer; the amphiphilic polymer bonded with the photosensitizer is coated with a hydrophobic small-molecule inhibitor and PAEMA (Polyacrylamide); wherein the amphiphilic polymer bonded with the photosensitizer comprises the photosensitizer, a hydrophilic chain segment and a hydrophobic chain segment. Precise drug delivery is achieved through characteristic transformation of the nano-carrier driven by tumor acidity, M2 type macrophages can be removed, dendritic cells can be induced to be mature, tumor cells can be killed, and therefore the synergistic anti-tumor effect of photodynamic therapy and immunotherapy is enhanced. Therefore, various drugs can be accurately delivered to target cells with different spatial distributions, so that the cell killing level and the antigen presenting cell mediated immunocompetence are enhanced at the same time.

The invention discloses an immune activation nano material based on chiral carbon dots as well as preparation and application of the immune activation nano material, a chiral structure is introduced to the surfaces of the prepared carbon dots, immune active molecules are modified, and then chiral conformation enhancement design is performed on the surfaces, so that the prepared nano material can remarkably improve the activation efficiency of an immune system; and the targeted recognition and response capability of immune cells is improved. The material disclosed by the invention has excellent biocompatibility and low toxicity, and has relatively high clinical transformation potential.

The invention belongs to the technical field of vaccines, and particularly relates to a manganese-based platelet carrier vaccine based on a biomimetic mineralization technology and application of the manganese-based platelet carrier vaccine in immunotherapy. A manganese-based shell is deposited on the surface of a platelet, immunocompetence molecules such as CD40L and PF4 are expressed on the surface of the platelet, dendritic cells (DC) can be activated by directly contacting or secreting cell factors, and antigen presentation is promoted; in addition, deposited manganese ions can activate a cGAS-STING pathway, and meanwhile, CD40 / CD80 / CD86 / MHC-II costimulatory molecular expression on the surface of the DC is up-regulated. The vaccine adjuvant provided by the invention can be used for loading an antigen to form a three-in-one vaccine complex of the antigen (loaded on a platelet membrane), the platelet and a manganese shell, so that not only is the natural targeting capability of the platelet retained, but also DC cross presentation is enhanced through continuous release of manganese ions, finally CD8 + T cells are synergistically activated to react with an antibody, and the immune response of the antigen is enhanced. The antiviral immune response of the body is enhanced.

The present invention relates to the use of an antibody or an immunologically active fragment thereof, which specifically binds to integrin β2, as an immuno-oncology agent. The chimeric and humanized antibodies of the present invention specifically bind to integrin β2, which is a tumor-specific antigen and is expressed on the cell membrane of M2 tumor-associated macrophages, and thus can be used as an antibody therapeutic agent for cancer treatment using a cancer cell death mechanism by immune cell activation, an antibody therapeutic agent for cancer treatment, or a cell therapeutic agent for cancer treatment, and can also be used for cancer diagnosis.

The invention relates to the technical field of biological medicines, and particularly discloses an egg yolk antibody for resisting canine interleukin as well as a preparation method and application of the egg yolk antibody. The egg yolk antibody is prepared by taking immunocompetence antigen epitope peptide of canine interleukin-31 as an immunogen, the antigen epitope peptide is obtained by predicting key antigen epitopes of IL-31 through an Antigenic tool and performing series optimization, a coding gene of the antigen epitope peptide is optimized by an escherichia coli codon to construct a recombinant expression vector, and high-purity antigen is obtained by inducible expression and purification. A laying hen is immunized by the antigen, after basic immunization and two times of booster immunization, the egg yolk antibody is extracted from egg yolk and purified to obtain the egg yolk antibody, and the ELISA of the egg yolk antibody is obviously superior to that of an antibody prepared by commercial canine IL-31 protein immunization. The egg yolk antibody can be specifically combined with canine IL-31, the histamine level in serum of a canine with pruritus is remarkably reduced, the atopic dermatitis related pruritus symptoms are effectively relieved, an efficient and safe biological treatment preparation is provided for canine IL-31 mediated pruritus diseases, and the egg yolk antibody has wide clinical application prospects.

The application discloses application of shrimp hemocyanin in a carrier protein of a hapten, and belongs to the technical field of biological medicines. Compared with KLH commonly used in the prior art, the shrimp hemocyanin provided in the application has good solubility, the whole antigen obtained by coupling the hapten has good solubility and is not easy to precipitate and separate out, and the immunogenicity of the shrimp hemocyanin is better than that of KLH; the whole antigen prepared by taking the shrimp hemocyanin as a carrier protein has better animal immunization activity than the whole antigen prepared by taking KLH as a carrier protein. The shrimp hemocyanin provided in the application is extracted from blood of prawns, the prawn breeding technology is mature, the shrimp hemocyanin is easy to obtain, and the purchase cost is low, so that the preparation cost of the shrimp hemocyanin is far lower than the purchase cost of KLH.

To provide an IL-12 production promoter containing honey as an active ingredient. [Solution] A composition for activating cellular immunity, containing sunflower honey as an active ingredient.

The invention discloses a tuna red meat immunity enhancing peptide and application thereof in enhancing immunity, and belongs to the technical field of biology. According to the invention, polypeptides with immunocompetence are extracted from tuna red meat, and the polypeptides comprise FLQGF and LAKFPDF. Experiments prove that the polypeptide prepared by the invention has no obvious toxic effect on cells, and can improve the proliferation rate and the phagocytic rate of macrophages and the release rate of NO to different degrees. An in-vitro immunomodulatory activity result shows that the LAKFPDF and the FLQGF can activate a TLR4 dependent NF-kB / MAPK signal channel, regulate and control the immune response of macrophages and play an immunomodulatory role. Research results of the invention provide a basis for high-value development and utilization of tuna red meat, and provide a new resource for preparation of immunopotentiation products.

The present invention relates to multiplex lateral flow immunochromatographic diagnostic devices configured to detect immune activity biomarkers in biological samples. The device is configured to detect granulysin as a biomarker indicative of cytotoxic immune effector activity and at least one secondary biomarker indicative of tissue-associated immune injury. In certain embodiments, the device comprises a sample pad, a conjugate pad containing labeled detection antibodies, a porous membrane comprising spatially distinct capture zones corresponding to granulysin and the secondary biomarker, a control zone, and an absorbent pad configured to facilitate capillary flow. Detection of granulysin and the secondary biomarker within a single multiplex device enables determination of immune activation state and tissue-associated immune context from a single biological sample. The device is suitable for rapid diagnostic use, including point-of-care and laboratory environments, using whole blood, plasma, serum, or related biological fluids.